Abstract
Over the past 20 years, biotechnology has pioneered the development of genetically engineered therapies that target specific aspects of the immune response. However, biologic agents are frequently immunogenic, requiring complex and labor intensive production processes and parenteral administration, resulting in high costs which limit both availability and access to treatment.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Firestein GS, Manning M (1999) Signal transduction and transcription factors in rheumatic diseases. Arthritis Rheum 42: 609–621
Piecyk M, Anderson P (2001) Signal transduction in rheumatoid arthritis. Best Practice and research. Clin Rheumatol 15: 789–803
Handel ML, Gurgis L (2001) Transcription factors. Best Practice and Research. Clin Rheumatol 15: 657–675
Angel P, Karin M (1991) The role of Jun, Fas and the AP-1 complex in cell proliferation and transformation. Biochem Biophys Acta 1072: 129–157
Kinne RW, Boehim S, Iftner T et al (1995) Synovial fibroblast-like cells strongly express jun-B and c-fas proto-oncogenes in rheumatoid and osteoarthritis. Scand J Rheumatol 101: Suppl 121–125
Deleuran BW, Chu GQ, Field M Brennan FM, Mitchell T, Feldmann M, Maini RN (1992) Localization of tumor necrosis factor receptors in the synovial tissue and cartilage pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 35: 1170–1178
Han Z, Boyle DL, Manning A et al (1998) AP-1 and NFKB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28: 197–208
Schett G, Tohidast-Akrad M, Smolen JS, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G (2000) Activation, differential localization and regulation of the stress activated protein kinases, extracellular signal regulated kinase, C-Jun N-terminal kinase and p38 mitogen activated protein kinase in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43: 2501–2502
Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS (2001) c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J. Clin Invest 108: 73–81
Han Z, Chang L, Yamanishi Y (2002) Joint damage and inflammation in c-Jun N-terminai kinase Z knockout mice with passive murine collagen-induced arthritis. Arthritis Rheum 46: 818–823
Herlaar E, Brown Z (1999) p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 5: 439-447
Shiojawa S, Shimizu K, Tanaka K et al (1997) Studies on the contribution of c-fos/AP-1 to arthritic joint destruction. J. Clin Invest 99: 1210–1216
Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL (2000) Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacol 47: 185–201
Adams JL, Badger AM, Kumar S, Lee JC (2001) p38 MAP kinase: Molecular target for the inhibition of pro-inflammatory cytokines. Prog Med Chem 38: 1–60
Handel ML, McMorrow LB, Gravellese EM (1995) Nuclear factor KB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 38: 1762–1770
Roshak AK, Callahan JF, Blake SM et al (2002) Small molecule inhibitors of NFKB for the treatment of inflammatory joint disease. Curr Opinion in Pharmacol 2: 316–321
Aupperle KB, Bennet BL, Boyle DL et al (1999) NFKB regulation by I kappa B kinase in primary fibroblast-like synoviocytes. J. Immunol 163: 427
Tak PP, Gerlag DM, Aupperle KG et al (2001 ) Inhibitor of nuclear factor kappa B kinase beta is a key regulator of synovial inflammation. Arthritis Rheum 44: 1897–1907
Miagkov AV, Kovalenko DV, Brown CE (1998) NF kappab activation provides the potential link between inflammation and hyperplasia in the arthritis joint. Proc Natl Head Sei USA 95: 13859–13864
Tomita T, Takeuchi E, Tomita N, Morishita R, Kaneko M, Yamamoto K, Nakase T, Seki H, Kato K, Kaneda Y et al (1999) Suppressed severity of collagen induced arthritis by in vivo transfection of nuclear factor kappa B decoy oligodeoxyonucleotides as a gene therapy. Arthritis Rheum 42: 2532–1242
Yokota A, Narazaki M, Shima Y, Murata N, Tanaka T, Suemura M, Yoshizaki K, Fujiwara H, Tsuyuguchi I, Kishimoto T (2001) Preferential and persistent activation of the STAT1 pathway in rheumatoid synovial cells. J. Rheum 28: 1952–1959
Crooke ST (1999) Molecular mechanisms of antisense drugs: human RnaseH. Antisense Nucleic Acid Drug Dev 9: 377
Moss ML, White JM, Andrews RC (2001) TACE and other ADAM proteases as targets for drugs discovery. Drug Discov Today 6(8): 417–426
Randle JC, Harding MW, Ku G et al (2001) ICE/Caspase-1 inhibitors as novel antiinflammatory drugs. Expert Opin Investig Drugs 10 (7): 1207–1209
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Birkhäuser Verlag Basel/Switzerland
About this chapter
Cite this chapter
Keystone, E.C., Haraoui, B. (2005). Future molecular targets. In: Day, R.O., Fürst, D.E., van Riel, P.L.C.M., Bresnihan, B. (eds) Antirheumatic Therapy: Actions and Outcomes. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-7726-7_4
Download citation
DOI: https://doi.org/10.1007/978-3-7643-7726-7_4
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-6595-0
Online ISBN: 978-3-7643-7726-7
eBook Packages: MedicineMedicine (R0)